Privacy preferences
Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.
  • Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Get in touch
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

SP Group

479.00 DKK+2.68 %4.9, 17.10
Less than 1K followers

SPG

NASDAQ Copenhagen

Chemicals

Basic Materials

Overview
Financials & Estimates
Ownership
Dividend
Investor views
Compare
+2.68 %
+1.27 %
+17.11 %
+26.72 %
+38.04 %
+69.26 %
+129.74 %
+27.06 %
+1,635.51 %

SP Group is a Danish plastic manufacturer that produces moulded items in plastics and plastic composites and performs surface coatings on metal items. The company is listed on the Nasdaq OMX Copenhagen Stock Exchange. It dates back to 1972 and is headquartered in Denmark. SP Group is a leading supplier of plastic-manufactured products to Danish industries. It services its clients through its factories in Denmark, Sweden, China, the USA, and Eastern Europe and its products are sold and marketed in around 90 countries. The Company offers a number of collective competencies through its different plastics processing plants which create synergy both internally among the plants and externally in partnerships with customers. The largest customer groups in terms of revenue are Healthcare, Cleantech, Food-related and Automotive, which adds up to around 75% of sales. SP Group is part of the OMX Copenhagen Mid Cap Index.

Read more
Market cap
5.8B DKK
Turnover
29.77M DKK
Revenue
2.95B
EBIT %
13.49 %
P/E
21.57
Dividend yield-%
0.84 %
Coverage
Disclaimer
Rasmus Køjborg
Rasmus Køjborg

Head of Research, Stables

Latest research

Latest analysis report

Released: 03.09.2026

Revenue and EBIT-%
EPS and dividend
Financial calendar
17.11
2026

Interim report Q3'26

All
Research
Webcasts
Press releases
ShowingAll content types

Revenue and EBIT-%

Revenue B

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Regulatory press release04.09.2026, 13.03

Share buy-back program at SP Group A/S

SP Group
Regulatory press release04.09.2026, 13.03

Aktietilbagekøbsprogram i SP Group A/S

SP Group
SP Group (Investment Case): Record H1 calls for new 2030 targets
Research03.09.2026, 11.30 by
Jacob Frehr, Rasmus Køjborg

SP Group (Investment Case): Record H1 calls for new 2030 targets

Today, we publish our updated SP Group investment case following the Q2 2026 report. SP Group delivered its third consecutive record quarter, with Q2 revenue up 44.6% (29.4% organic) and guidance raised twice in six weeks to 24–30% growth, while the H1 EBITDA margin held at 20.3%. With consensus pointing to DKK 4.26bn revenue in 2027, the 2030 ambition of DKK 4.5bn looks attainable already in 2028, and the 2030 targets look set to be revisited.

SP Group

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Regulatory press release28.08.2026, 13.18

Share buy-back program at SP Group A/S

SP Group
Regulatory press release28.08.2026, 13.18

Aktietilbagekøbsprogram i SP Group A/S

SP Group
Regulatory press release24.08.2026, 16.35

Correction: Management’s or Related parties’ trading with SP Group A/S shares

SP Group
Regulatory press release24.08.2026, 16.35

Rettelse: Indberetning af ledende medarbejderes og disses nærtståendes transaktioner i SP Group A/S

SP Group
Regulatory press release24.08.2026, 13.29

Management’s or Related parties’ trading with SP Group A/S shares

SP Group
Regulatory press release24.08.2026, 13.29

Indberetning af ledende medarbejderes og disses nærtståendes transaktioner i SP Group A/S

SP Group
SP Group – Presentation of the quarterly report for Q2 2026
Webcast21.08.2026, 15.00

SP Group – Presentation of the quarterly report for Q2 2026

SP Group is set to release their quarterly report for Q2 2026 on Thursday 20 August 2026. On Friday 21 August 2026 at 3:00 PM, CEO Lars Bering and CFO Allan Jeppesen will present the results and answer questions from the audience during an online live event.

SP Group
SP Group – Præsentation af regnskabet for 2. kvartal 2026
Webcast21.08.2026, 12.00

SP Group – Præsentation af regnskabet for 2. kvartal 2026

SP Group ventes at offentliggøre sit regnskab for 2. kvartal 2026, og dermed 1. halvår 2026 – torsdag d. 20. august 2026. Dagen efter – fredag d. 21. august kl. 12.00 - kan du høre ledelsens udlægning af hvordan første halvdel af 2026 er forløbet for SP Group, når vi har CEO Lars Bering og CFO Allan Jeppesen igennem på et virtuelt event.

SP Group
Regulatory press release21.08.2026, 11.52

Share buy-back program at SP Group A/S

SP Group
Regulatory press release21.08.2026, 11.52

Aktietilbagekøbsprogram i SP Group A/S

SP Group
HCA Morgenbørs 21/08 - BioPorto CFO-interview og svag positiv åbning
Video21.08.2026, 09.32 by
Michael Friis, Jacob Frehr

HCA Morgenbørs 21/08 - BioPorto CFO-interview og svag positiv åbning

Udsigt til en flad til svag positiv åbning i Europa. Scott Bessent redningsplan holdt ikke længe Fokus på regnskabsaktuelle Better Collective, Bavarian. Gæst i studiet her til morgen er BioPorto CFO Klaus Juhl Wulff.

BioPortoBetter CollectiveBavarian NordicGN Store NordSP GroupGubraNorth MediaNovonesisFLSmidth & Co.
HCA dagens aktienyheder 21/08/2026: Biomar, North Media og SP Group
Analyst Comment21.08.2026, 08.54 by
Rasmus Køjborg, Victor Skriver

HCA dagens aktienyheder 21/08/2026: Biomar, North Media og SP Group

Rekord på både omsætning og indtjening hos SP Group, som opjusterer for anden gang i år på ryggen af et britisk opkøb, North Media leverer sit endelige Q2-regnskab få dage efter en nedjustering af helåret, og vi løfter sløret for vores allerførste investeringscase på nyligt børsnoterede BioMar.

BioMar GroupNorth MediaSP Group
Mød ledelsen i Ascelia Pharma, Lundbeck, SP Group, WindowMaster og North Media og stil dine spørgsmål til dagens investorpræsentationer
Analyst Comment21.08.2026, 08.30 by
Victor Skriver

Mød ledelsen i Ascelia Pharma, Lundbeck, SP Group, WindowMaster og North Media og stil dine spørgsmål til dagens investorpræsentationer

I dag afholder vi fem online investorevents. Kl. 10:00 præsenterer Ascelia Pharma CEO Magnus Corfitzen resultaterne for Q2 2026. Kl. 11:00 præsenterer Lundbeck Jens Høyer, Vice President & Head of Investor Relations, halvårsrapporten for H1 2026. Kl. 12:00 præsenterer SP Group CEO Lars Bering og CFO Allan Jeppesen regnskabet for 2. kvartal 2026. Kl. 13:00 præsenterer WindowMaster CEO Erik Boyter og CFO Steen Overgaard Sørensen halvårsrapporten for H1 2026. Kl. 14:00 gennemgår North Medias ledelse regnskabet for 2. kvartal 2026. Tilmeld dig og stil dine spørgsmål allerede nu.

SP GroupAscelia PharmaLundbeckWindowMaster InternationalNorth Media
Analyst Comment20.08.2026, 11.37 by
Rasmus Køjborg

SP Group: Q2 2026 financial report shows new records in revenue and earnings

SP Group released its Q2 2026 report this morning, covering the first half of 2026, and reported record sales and earnings. At the same time, the sales guidance for 2026 has been raised for the second time this year, this time following the acquisition of OGM Moulding Ltd. in the UK, which was announced yesterday.

SP Group
Regulatory press release20.08.2026, 10.34

SP Group's Interim Report for the first half of 2026

SP Group
Regulatory press release20.08.2026, 10.34

SP Groups delårsrapport for 1. halvår 2026

SP Group
HCA dagens aktienyheder 20/08/2026: SP Group, GrønlandsBANKEN, GreenMobility, Ascelia Pharma, Gubra, BioPorto, ALK-Abelló og ExpreS2ion Biotech
Analyst Comment20.08.2026, 08.55 by
Michael Friis, Rasmus Køjborg

HCA dagens aktienyheder 20/08/2026: SP Group, GrønlandsBANKEN, GreenMobility, Ascelia Pharma, Gubra, BioPorto, ALK-Abelló og ExpreS2ion Biotech

SP Group køber britiske OGM Moulding for ca. DKK 158 mio. og opjusterer omsætningsforventningerne til 2026. GrønlandsBANKEN leverer solid fremgang på bundlinjen i H1 med et stærkt Q2, der opvejer en svagere start på året. GreenMobility lander flerårig ladeaftale med EDF, hvor franskmændene tager hele investeringen og driftsomkostningerne. Ascelia Pharma halverer driftsunderskuddet i Q2 og har kapital ind i Q2 2027 frem mod FDA-mødet den 9. september. Gubra melder om stærkt klinisk pipeline-momentum, og CRO-forretningen viser tegn på at have fundet bunden. BioPorto ser underliggende NGAL-vækst på 23% og tilføjer seks nye amerikanske hospitaler, mens 2026-guidance fastholdes. ALK-Abelló slår konsensus på både top- og bundlinje i Q2 og løfter bunden af omsætningsguidancen for 2026. ExpreS2ion Biotech rapporterer HER2-antistofrespons hos 12 ud af 13 evaluerbare patienter og ingen dosisbegrænsende toksicitet.

SP GroupGrønlandsbankenGreenMobilityAscelia PharmaGubraBioPortoALK-Abelló